Parkinson’s Disease Drugs Market Size, Share, Trends and Industry Analysis By Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors), Route of Administration (Oral, Injection, Transdermal), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) & Regional Forecast, 2026-2034

Last Updated: December 22, 2025 | Format: PDF | Report ID: FBI100655

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Unit	Value (USD Billion)
Growth Rate	CAGR of 8.22% from 2026 to 2034
Segmentation	By Drug Class Decarboxylase Inhibitors Dopamine Agonists Monoamine Oxidase Type B (MAO-B) Inhibitor Catechol-O-Methyltransferase (COMT) Inhibitors Others
	By Route of Administration Oral Injection Transdermal
	By Distribution Channels Hospital Pharmacy Retail Pharmacy Online Pharmacy
	By Geography North America (USA and Canada) Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) Latin America (Brazil, Mexico and Rest of Latin America) Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)